CMPR Legislation Timeline: From Voluntary Listing to Mandatory Registration

1. Key takeaways

Medical device regulation in Hong Kong, China is moving from voluntary listing to statutory registration. 5 published milestones frame the shift: the preparatory office for the Centre for Medical Products Regulation was established under the Department of Health on 5 June 2024; the establishment timetable and the primary evaluation roadmap were announced on 26 June 2025; the Hong Kong Centre for Medical Products Regulation (CMPR) is to be established before the end of 2026; legislative proposals on device regulation are to be submitted to the Legislative Council in 2026; and once legislation is in force, all medical devices supplied in the territory, unless exempt, must be registered. The direct implication is that completing an MDACS listing now is the lowest-cost move available during the transition.

The timing is unusual in that the commitment appears in several unrelated official documents, each produced for a different purpose. That redundancy is itself useful: it means the legislative timetable is not a single department’s aspiration but a position the government has repeated when answering the legislature, when presenting to industry and when defending its budget.

The GRZAN view. Companies that treat the transition as background noise will rebuild their files twice; companies that build for portability now will rebuild once, and cheaply.

2. Legal basis

Legislative and policy record. The Legislative Council Panel on Health Services background brief for the meeting of 10 April 2026, document CB3-261-4 prepared by the Secretariat on 31 March 2026, addresses the establishment of CMPR at paragraphs 15 to 16. The government reply to a Legislative Council question, press release P2025070900329 of 9 July 2025, records the establishment timetable and the legislative proposal in its final paragraph. The Department of Health symposium press release P2026020300240 of 3 February 2026 reports the Director of Health on the establishment of the centre in 2026 and the submission of legislative proposals in the same year. The Commerce and Digital policy document on the establishment of CMPR and the roadmap for primary evaluation, paper 41 of the wholesale and retail working group, records the preparatory office at paragraph 4 and the timetable announcement at paragraph 6. The Finance Committee reply on the 2026-27 Estimates, question 2202, covers the 1+ mechanism data and legislative preparation at items 1 to 2.

Two dates carry the schedule. The preparatory office of 5 June 2024 marks the start of institutional build-out, and the announcement of 26 June 2025 marks the point at which the establishment timetable and the primary evaluation roadmap became public policy rather than internal planning.

3. Expert insights

The 2026 legislative commitment is a promise, not an intention. The government has expressed it consistently. The Legislative Council reply of 9 July 2025 said submission was expected the following year; the Director of Health said publicly on 3 February 2026 that the government would submit legislative proposals to regulate medical devices this year; and the Legislative Council brief for the meeting of 10 April 2026 records that the government will submit in 2026. Three sources, three audiences, one date. That consistency is what gives the date weight.

Unless exempt, all devices must be registered is the widest statement in the set. It implies that once the legislation commences, the MDACS scope is likely to move beyond the present Class II and above limit and extend to all devices. Class I GMD and Class A IVDMD, which today sit outside listing obligations, may be brought in. A product portfolio review that counts only currently listed devices will understate future exposure.

Integration is a structural change, not a renaming. CMPR will consolidate and reorganise the functions and staff of the Department of Health service units that presently deal separately with western medicines, Chinese medicines and medical devices. For a company already listed, the direct consequence is that the contact point, the form set and the numbering rules may all change at once, which is a systems problem as much as a regulatory one.

Transitional evidence can be reused. The government has repeatedly encouraged the industry to list under MDACS early, so as to prepare for transition to the future statutory framework. Technical documentation, quality system evidence and post-market records already assembled are the assets that move across most easily, provided they were structured for a reviewer rather than for internal use.

4. Practical recommendations

• Do not wait for legislation. Use Phase C procurement and use-side obligations as the immediate driver to start listing, and treat legislative preparation as the long-term driver for evidence design.
• Build a portable evidence pack. Organise the conformity checklist, technical file summaries, system certificates and post-market records in an IMDRF structure of the kind CMPR is likely to adopt, to reduce future reconstruction.
• Track three sources. Follow the Legislative Council Panel on Health Services papers, Department of Health press releases, and the MDD page on developments in the administrative control system.
• Write change clauses into contracts. Include a provision in the LRP agreement for adjusting the entity and its obligations after a regulatory change, so that the relationship does not have to be renegotiated from scratch.
• Map low-class products now. Identify devices currently outside listing obligations that would fall in scope under an all-device registration model, and estimate the evidence gap for each.

5. Verification checklist

• □ Target establishment of CMPR recorded as the end of 2026, on the official position.
• □ Official statements on the 2026 legislative proposals recorded, with the three sources noted.
• □ Low-class devices in the portfolio assessed for future inclusion in scope.
• □ Evidence pack structured for portability into a statutory regime.
• □ Subscriptions in place for Legislative Council panel papers and MDD development updates.
• □ LRP agreement contains a regulatory change adjustment clause.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages Medical Device Administrative Control System (MDACS) listings, coordinates import licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com